Venclose, Inc.

Venclose, Inc. specializes in innovative venous technologies aimed at treating superficial vein disorders through advanced medical devices, improving procedural efficiency in healthcare. Venclose, Inc. , founded in 2014 in San Jose, US, focuses on developing venous technologies.

The company has raised a total of USD 27. 1 mn through funding, with the most recent Series C round led by Ally Bridge Group in November 2019. The company does not report any changes in business operations or ownership structure, and it operates out of its headquarters in San Jose. Jerry Gibson serves as the CEO.

Venclose, Inc. offers advanced venous technologies to address superficial venous anatomy challenges. Their main products include the Venclose™ EVSRF Catheter and Venclose Maven™ Catheter, designed for endovascular coagulation in patients suffering from superficial vein reflux. These products utilize advanced radiofrequency technology for improved procedural efficiency and target healthcare providers, primarily hospitals and outpatient clinics across the United States.

Venclose, Inc. employs a direct-to-business model, selling its medical devices to healthcare institutions. Revenue is generated through the sale of the Venclose™ EVSRF Catheter and Venclose Maven™ Catheter, as well as the digiRF™ Generator essential for catheter operation. This pricing reflects the specialized nature of the products, which are marketed as solutions for chronic venous disease, with customer engagement supported by clinical education.

In November 2019, Venclose, Inc. secured USD 27. 1 mn in Series C funding aimed at supporting its growth strategy. The company is focused on expanding its product offerings and enhancing its market presence.

Specific plans include the development of new devices tailored for venous treatments and potential entry into new geographic markets, although specific regions have yet to be disclosed. The funding is expected to be utilized for product development and market expansion initiatives.